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Polyfunctionality and cytotoxic activity dictate CD8+ T-cell efficacy in the eradication of infected 
and malignant cells. The induction of these effector functions depends on the specific interaction 
between the TCR and its cognate peptide-MHC class I complex, in addition to signals provided by 
co-stimulatory or co-inhibitory receptors, which can further regulate these functions. Among these 
receptors, the role of 2B4 is contested, as it has been described as either co-stimulatory or co-
inhibitory in modulating T-cell functions. We therefore combined functional, transcriptional and 
epigenetic approaches to further characterize the impact of disrupting the interaction of 2B4 with its 
ligand CD48, on the activity of human effector CD8+ T-cell clones. In this setting, we show that the 
2B4-CD48 axis is involved in the fine-tuning of CD8+ T-cell effector function upon antigenic 
stimulation. Blocking this interaction resulted in reduced CD8+ T-cell clone-mediated cytolytic 
activity, together with a subtle drop in the expression of genes involved in effector function 
regulation. Our results also imply a variable contribution of the 2B4-CD48 interaction to the 
modulation of CD8+ T-cell functional properties, potentially linked to intrinsic levels of T-bet 
expression and TCR avidity. The present study thus provides further insights into the role of the 
2B4-CD48 interaction in the fine regulation of CD8+ T-cell effector function upon antigenic 
stimulation. 





CD8+ T-cells are key players in the fight against viruses and tumors. In recent years, a number of 
studies have emphasized the importance of functional cellular properties, like cytolytic capacity and 
the ability to secrete soluble effector molecules (i.e. cytokines and chemokines), in dictating CD8+ 
T-cell efficacy in infectious or malignant settings 2-4. The induction and regulation of potent 
effector functions is directly related to the level of activation received by T-cells upon engagement 
of their cognate antigen 5. T-cell activation in turn depends on the multiple molecular interactions 
that occur between a T-cell and its cognate, epitope-bearing target. These interactions include: i) the 
binding of the TCR and CD8 co-receptor to the peptide-MHC class I complex (pMHCI) (reviewed 
in 6); ii) engagement of co-stimulatory or co-inhibitory receptor/ligand pairs (reviewed in 7); and, 
iii) the effect of soluble factors, such as cytokines 8-10, which collectively influence T-cell function. 
These different inputs, also known as Signal 1 (pMHCI antigen), Signal 2 (co-stimulation/co-
inhibition) and Signal 3 (inflammatory cytokines), determine the choice between full T-cell 
activation and tolerance (reviewed in 11).  
 
While the specificity and strength (i.e. avidity) of the TCR/pMHCI interaction constitute the major 
features that determine the outcome of CD8+ T-cell activation and function, the contribution of 
TCR/pMHCI independent factors is less clear. It is therefore important to provide further insight 
into the regulation of CD8+ T-cell effector functions, including cytolysis and cytokine production, 
by various immunomodulatory cell surface molecules (Signal 2). CD8+ T-cells express multiple co-
stimulatory/co-inhibitory receptors, designed to regulate their function 12-14. In recent years, much 
work has focused on clarifying the role of co-inhibitory molecules such as PD-1 and CTLA-4 15-17, 
but the exact role of a number of other cell surface receptors remains to be fully understood. In this 
report, we focused our attention on 2B4 (CD244). 2B4 is a member of the signaling lymphocyte 
activation molecule (SLAM) family, and has been implicated in the regulation of co-stimulation, 




cytokine production and cytotoxic activity of CD8+ T-cells 18-20. Its only known ligand in humans is 
CD48, a molecule broadly expressed on hematopoietic cells 21-23. Interestingly, blockade of the 
2B4-CD48 interaction has been shown to both enhance 24-26 and inhibit 27, 28 CD8+ T-cell responses 
in virally infected human subjects and various murine disease models. Thus, the 2B4-CD48 axis 
presents an intriguing case of “dual functionality” 29, 30, with both co-stimulatory or co-inhibitory 
effects on modulating T-cell function. 
 
The interaction of co-stimulatory and co-inhibitory receptors with their cognate ligands culminates 
in the expression of genes specific to T-cell effector function. In addition, gene transcriptional 
activity is likely to be regulated at the epigenetic level. Recent evidence indicates that the distinct 
expression patterns of T-cell functional genes are indeed controlled by epigenetic modifications at 
the chromatin level 31-35. Chromatin structure is dynamic and can be found in two basic states: an 
open chromatin (euchromatin) state that is accessible to DNA-binding proteins (e.g. transcription 
factors, transcriptional activators or repressors, and RNA polymerase) and thus facilitates active 
gene transcription; and a closed chromatin (heterochromatin) state that is non-permissive to 
transcriptional machinery and is therefore associated with gene silencing 36. Several epigenetic 
markers (i.e. chemical modifications of DNA and histones) have been identified in association with 
specific chromatin states and transcriptional levels. For instance, covalent modifications of the 
amino-terminal tails of histones (e.g. histones H2A, H2B, H3 and H4) have been shown to regulate 
the chromatin state and consequently gene transcription 37-40. Assessing the contribution of 
epigenetic changes to the control of genetic transcriptional profiles is thus very important in 
broadening our understanding of CD8+ T-cell effector function.  
 
We therefore studied the role that the 2B4-CD48 interaction plays in regulating antigen specific 
CD8+ T-cell activity at the transcriptional, functional and epigenetic levels, using CD8+ T-cell 




clones. This approach enabled us to investigate the impact of blocking the 2B4-CD48 pathway on 
the induction of cytolysis and cytokine production by CD8+ T-cells upon cognate antigen 
stimulation, while controlling for TCR diversity. Chromatin immunoprecipitation in combination 
with high-throughput sequencing (CHIP-Seq) was also performed to assess histone modifications. 
Specifically, we analyzed the trimethylation of H3K4 (H3K4me3) and H3K27 (H3K27me3), which 
are associated with an open chromatin state (active gene expression), and a closed chromatin state 
(repressed gene expression), respectively. This comprehensive study revealed a subtle positive fine-
tuning of CD8+ T-cell effector functions by the 2B4-CD48 interaction at the clonal level. 
 





Expression of 2B4 on CD8+ T-cells with potent effector functions ex vivo and in vitro 
Based on the expression of diverse cell surface receptors, such as CD45RA, CCR7, CD28 and 
CD27, the CD8+ T-cell population can be divided into distinct subsets, referred to as naïve, central 
memory (CM), and early, intermediate or late effector/memory (E-EM, I-EM, L-EM, respectively) 
cells 41. Although there is ongoing debate as to the stimulatory or inhibitory influence of 2B4 on 
CD8+ T-lymphocyte function, its expression is known to be particularly strong on highly 
differentiated effector/memory CD8+ T-cells, which exhibit potent effector functions 13, 42, 43. In 
comparison to other co-inhibitory (i.e. CD160, PD-1, Tim-3, BTLA, LAG-3 and CTLA-4) or co-
stimulatory receptors (i.e. LIGHT, 4-1BB, CD28 and CD38), the expression of 2B4 on these cells is 
particularly striking (Figure 1a and 13, 43). Of the receptors mentioned, 2B4 is the most abundant on 
the CD8+ T-cell surface (Figure 1a), and its expression is stable upon activation (Figure 1b). Based 
on this expression pattern, highly differentiated CD8+ T-cells may be a particularly relevant setting 
to study the influence of the 2B4-CD48 interaction on effector function upon TCR stimulation. 
However, evaluating the role of such interactions in ex vivo PBMC samples encounters difficulties 
relating to the heterogeneity of this population, in terms of gene expression and clonotypic 
composition. We therefore decided to study antigen-specific CD8+ T-cell clones expanded in vitro, 
that were representative of highly differentiated effector/memory CD8+ T-cells both in terms of 
phenotype and co-stimulatory and co-inhibitory receptor expression. For this purpose, we selected 
three previously characterized CD8+ T-cell clones, namely G12C, G10A and H8B 5, 44, specific for 
the HLA-B27-restricted HIV-derived epitope KK10 (p24 Gag263-272; KRWIILGLNK). These clones 
displayed an intermediate effector/memory phenotype (Figure 1e), and a co-stimulatory and co-
inhibitory receptor (in particular 2B4) expression pattern similar to that of intermediate/late 
effector/memory CD8+ T-cells (Figures 1c, 1d and 1f). These tools enabled us to assess the 
influence of the 2B4-CD48 interaction on the induction of effector CD8+ T-cell functions upon 




stimulation with a cognate antigen at a clonal level. 
 
Negative impact of blocking 2B4-CD48 signaling on effector function gene expression 
We began by assessing the impact of blocking 2B4-CD48 signaling on the expression of genes 
relating to T-cell function, differentiation, and transcription factors, following TCR mediated 
activation. For this purpose, G12C, G10A and H8B were stimulated for 3 hours in the presence of 
KK10 peptide-pulsed HLA-matched targets (722.221; a human MHC class I-deficient B-cell line, 
transfected with HLA-B27 and verified for CD48 expression), before being purified by FACS 
sorting. The shorter 3 hour (as opposed to the conventional 6 hour) activation period was chosen to 
minimize mRNA degradation. Blockade of the 2B4-CD48 interaction was achieved by pre-
incubating both CD8+ T-cell clones and antigen presenting cells with a saturating concentration of 
an anti-CD48 blocking antibody 13, 42, 43. Gene expression profiles of FACS-sorted CD8+ T-cell 
clones were then generated using the Fluidigm BioMark™ platform technology, allowing for a 
high-throughput assessment of the expression of up to 96 genes by RT-PCR 45. The 96 gene targets 
were selected based on their relevance to T-cell function 45.  Cluster analyses showed that, as 
expected, the transcription of a series of genes relating to effector function was triggered in all three 
clones upon antigenic stimulation (Figure 2a). Meanwhile, the expression levels of these genes 
were lowered upon 2B4-CD48 blockade (Figure 2a). The degree of gene upregulation upon 
stimulation (expressed as Et values, equivalent to 40-Ct) was then calculated in the presence or in 
the absence of the anti-CD48 antibody (Figure 2b). Overall, blocking the 2B4-CD48 interaction 
resulted in a modest reduction in effector molecule gene expression (e.g. IFN, TNF, MIP-1, 
perforin and granzyme B), but without overriding the expression of genes following TCR signaling. 
Of note, while H8B upregulated fewer genes compared to G12C and G10A upon cognate antigenic 
stimulation (Figure 2a), blocking 2B4-CD48 signal transduction resulted in a more apparent 
decrease in the expression of active genes, particularly those encoding effector molecules and 




receptors (Figure 2a and 2b). Overall, these data suggest that in our clonal system, 2B4 acts as a co-
stimulatory receptor, by contributing to the optimal induction of effector functions in CD8+ T-cells. 
 
Reduced CD8+ T-cell cytolytic capacity upon 2B4-CD48 interaction blockade  
We also analyzed the effect of 2B4-CD48 blockade directly on the functional attributes of the three 
CD8+ T-cell clones upon antigenic stimulation, assessing their ability to produce effector cytokines 
and degranulate. Although blocking 2B4-CD48 had hardly any effect on the degranulation capacity 
of the clones (i.e. upregulation of CD107a upon activation; Figure 3a), it significantly reduced their 
cytolytic activity (i.e. lysis of peptide loaded target cells in FATAL assays; Figure 3b and 3c). The 
effect was especially apparent at the earlier time-point of 6 hours (Figure 3c). The negative impact 
on cytolytic capacity of 2B4-CD48 blockade was also clearer with H8B, and was still found at 12h 
(Figure 3b and 3c). The influence of 2B4-CD48 blocking on the production of the cytokines IFN, 
TNF, MIP-1 and IL-2 (assessed by intracellular cytokine staining upon antigenic stimulation), had 
negligible effect (Figure 3b).  Taken together, these transcriptional and functional data denote a 
moderate but steady effect of blocking the 2B4-CD48 signal, and suggest that the 2B4-CD48 
interaction contributes positively to the fine-tuning of CD8+ T-cell effector functions. This was 
more obvious with H8B, which was apparently more sensitive to 2B4-CD48 blockade compared to 
G12C and G10A, especially at the level of effector gene transcription and killing activity.  
 
Epigenetic regulation of CD8+ T-cell effector function 
We next used the ChIP-Seq approach to determine if clues relating to the subtle effects of blocking 
the 2B4-CD48 interaction seen at the functional level could be obtained from epigenetic analysis 
(i.e. by monitoring chromatin structure). Recent studies have shown a close relationship between 
gene expression and the distribution of chromatin histone methylation sites 31-35. In particular, the 
trimethylation of H3K4 (H3K4me3) and H3K27 (H3K27me3) correlate positively and negatively 




with gene transcription, respectively 31, 34. In order to achieve a high level of accuracy, the general 
ChIP-Seq technique requires a high starting cell number (i.e. 1 to 10 x 106 depending on the affinity 
of Abs and efficiency of ChIP), which emphasizes the need to use in vitro expanded CD8+ T-cell 
clones. Genomic H3K4me3 and H3K27me3 ChIP libraries (composed of 270 bp DNA fragments) 
were constructed for the three CD8+ T-cells clones in a resting state (due to the difficulty of 
predicting chromatin remodeling kinetics on activation) and sequenced using the Miseq system 
(Illumina). Non-IP libraries, obtained from each of the clones, were used for reference. In all 
clones, we found a high degree of H3K4me3 associated with the promoter regions of effector 
molecule-encoding genes, including PRF1, GZMB, LAMP1, and TBX21 (Figure 4a), while there 
was little sign of H3K27me3 in these regions (data not shown). Our data showing the active 
transcription of these genes is similar to observations previously made in the human 
effector/memory CD8+ T-cell subset 1, 31, 34, 35, 37. In addition, we analyzed the promoter regions of 
genes related to the 2B4 co-stimulatory pathway. Besides genes encoding the 2B4 receptor 
(CD244) and ligand (CD48), we also focused on other genes implicated in 2B4-mediated signal 
transduction and its co-stimulatory function. Namely, we looked at the epigenetic regulation of 
SH2D1A and FYN, which encode the intracellular adaptor molecule SLAM-associated protein 
(SAP) and the Src-related kinase Fyn, respectively 46. The promoter regions of these genes were 
enriched in H3K4me3 ChIP-Seq samples, indicating an open chromatin state and high levels of 
transcriptional activity (Figure 4b). In contrast, we observed no H3K27me3 in these regions (data 
not shown). In line with these observations, the clones had high basal levels of mRNA transcripts 
for these functional molecules, including TBX21 and SH2D1A (Figure 4c). These results suggest 
that the effector functions of all CD8+ T-cell clones used in our study, are poised for induction 
through both TCR and 2B4 mediated pathways. 
 
A potential link between T-bet expression and CD8+ T-cell TCR avidity  




T-bet (also known as Tbx-21) is an important transcription factor, responsible for the regulation of 
gene expression levels of effector molecules such as granzyme B, perforin and IFNγ, upon TCR 
stimulation 47. We thus explored the possibility of the subtle reduction in CD8+ T-cell function, 
observed following 2B4-CD48 blockade, being related to changes in T-bet expression. Similarly to 
ex vivo PBMC-derived effector/memory CD8+ T-cells (Figure 5a), all three CD8+ T-cell clones 
expressed constitutively high levels of T-bet (Figure 5b). We observed no impact of 2B4-CD48 
blocking on TBX21 (Figure 2b) and T-bet (Figures 5b and 5c) expression levels in the clones, 
indicating that 2B4 mediated co-stimulatory effect most likely does not operate by increasing T-bet 
expression. However, upon antigenic stimulation, T-bet expression was barely increased in H8B, 
contrasting with G12C and G10A (Figure 5b), in line with the TBX21 transcriptional data (Figure 
2b). Overall, poor T-bet upregulation, together with weak effector gene expression and cytokine 
secretion upon antigenic stimulation in H8B, imply a suboptimal TCR mediated activation of this 
clone compared to G12C and G10A. In line with its low responsiveness to the cognate antigen, 
H8B displays indeed a considerably lower TCR avidity than the two other clones, as assessed using 
tetramer dilution assays (Figure 5d)44. Collectively, these data suggest that the higher susceptibility 
of H8B to 2B4-CD48 blockade may be related to its lower TCR avidity and consequently ability of 
initiate T-bet expression. Whether 2B4-CD48 signaling may partly compensate for a weak 
upregulation of T-bet due to suboptimal activation upon cognate antigen engagement will therefore 
merit further investigation.  
 





The 2B4-CD48 interaction holds a complex biological role in T-lymphocytes. It has been reported 
to mediate both activatory and inhibitory effects on the induction of T-cell functions in mouse and 
human studies 24-30. Highly differentiated CD8+ T-cells express high levels of 2B4 13, 42, 43, which 
may be crucial for regulating the potent effector functions deployed by these cells. To gain further 
insight into the role of the 2B4-CD48 interaction in such effector/memory CD8+ T-cells, we have 
used CD8+ T-cell clones of defined specificity, TCR avidity and phenotype to study the impact of 
blocking the 2B4-CD48 signal upon stimulation with a cognate antigen. Changes in CD8+ T-cell 
effector activity were subsequently monitored at the transcriptional, functional and epigenetic 
levels. We report a subtle co-stimulatory effect of the 2B4-CD48 interaction on CD8+ T-cell 
function, in terms of effector molecule gene expression and in particular, cytotoxicity. Since the 
observed reduction in specific target cell lysis (following the disruption of the 2B4-CD48 
interaction) could not be attributed to changes in either perforin expression (data not shown) or 
degranulation, it is possible that the effect can be explained by changes in signaling. It has been 
previously shown that the co-stimulatory role of 2B4 on T-cells is related to the levels of SAP 
expressed within these cells 46, 48, an intracellular signaling molecule associated with the control of 
cytotoxicity in CD8+ T-cells 49. Furthermore, defective 2B4-SAP signaling was reported to result in 
the diminished capacity of CD8+ T-cells to lyse cognate target cells infected with Epstein-Barr 
virus (EBV), due in part to the suboptimal recruitment of perforin to lipid rafts and improper T-
cell/target cell association 49. The work presented here is in agreement with these reports, as our 
system of CD8+ T-cell clones not only presented high levels of SH2D1A SAP-encoding transcripts 
(together with an open chromatin state associated with the SH2D1A promoter), but also exhibited 
substantially reduced on-target cytotoxicity following the disruption of the 2B4-SAP signaling 
network. Interestingly, SAP-deficient CD8+ T-cells have been shown to express normal levels of 




lytic molecules (including perforin) and effector cytokines (including IFNγ and IL-2), also 
consistent with our own findings on blocking the 2B4-CD48 interaction. 
 
Although the co-stimulatory impact of the 2B4-CD48 interaction remained relatively modest in the 
present setting, our findings argue against the definition of 2B4 as a marker of T-cell dysfunction 30, 
50, 51, especially in terminally differentiated CD8+ T-cells. We previously showed that the co-
expression of 2B4 and PD-1 on HIV-specific CD8+ T-cells was associated with suboptimal cellular 
functionality 13, 42, 43, 52. The CD8+ T-cell clones used in the present study expressed mainly 2B4, 
but not PD-1, like CMV-specific CD8+ T-cells, which display a more differentiated phenotype 
compared to HIV-specific CD8+ T-cells 53. The co-expression of various co-stimulatory or co-
inhibitory molecules certainly complicates the study of the contribution of a given receptor, and 
may explain divergent outcomes and conclusions. Our present findings are also in agreement with a 
recently published study, pointing towards the potential benefits of elevated 2B4 expression on the 
surface of cytolytic HIV-specific CD8+ T-cells 54. Even though the number of clones studied in the 
present work was limited, our data point towards the possibility that strong TCR signaling and T-
bet upregulation, for instance exhibited by high avidity CD8+ T-cells, may override the need for 
2B4-CD48 mediated co-stimulation. The superior contribution of a strong TCR signal may in part 
explain the subtle effects on T-cell function observed upon blockade of the 2B4-CD48 interaction, 
but the more pronounced effect on the low TCR avidity clone with a weak capacity to upregulate T-
bet upon activation. It is thus tempting to speculate that the co-stimulatory effect mediated by the 
2B4-CD48 interaction may serve to compensate for a suboptimal TCR activation signal, for 
instance helping to optimize the functional response of effector CD8+ T-cells displaying low TCR 
avidity. 
 




While the use of CD8+ T-cell clones presents obvious advantages over PBMC-derived ex-vivo 
samples when it comes to performing detailed assessment of T-cell functional activity, it also has a 
number of drawbacks. Firstly, the clones are not representative of the diverse CD8+ T-lymphocyte 
subsets encountered in vivo. Secondly, the rigorous in vitro propagation of CD8+ T-cells is likely to 
alter their intrinsic properties, compared to their ex vivo clonotypic equivalents. It would therefore 
be important to perform similar studies on ex vivo isolated effector/memory CD8+ T-cell subsets, 
differing in their surface 2B4 expression levels. Finally, the 2B4-CD48 interaction may exert a 
different influence over the function of CD8+ T-cells at an earlier stage of differentiation, as 
suggested by a previous study 30, which could further explain the subtle effect observed in a setting 
of highly differentiated CD8+ T-cell clones.  Accordingly, the chromatin structure and permissive 
epigenetic signatures for given genes have also been shown to change with T-cell differentiation 31. 
In summary, we used here a combination of functional, transcriptional and epigenetic approaches to 
create a comprehensive picture of the parameters affecting the functional activity of human CD8+ 
T-cell clones. The present study provides further insights into the co-stimulatory role of the 2B4-
CD48 interaction, engaged to fine-tune CD8+ T-cell effector function upon antigenic stimulation. 





PBMCs and CD8+ T-cell clones. Peripheral blood mononuclear cell (PBMC) samples were 
obtained from healthy individuals with the approval by the relevant local institutional (at the 
Hospital Pitie Salpetriere) review board and ethics committee, and informed consent in 
accordance with the Declaration of Helsinki. CD8+ T-cell clones (G12C, G10A and H8B) specific 
for the HLA-B*2705 (HLA-B27 from hereon)-restricted p24 Gag epitope KK10 (KRWIILGLNK, 
Gag263–272) were generated and expanded as described previously 
5, 44. An HLA-B27+, CD48+ 
Epstein–Barr virus (EBV)-transformed 722.221 B-cell line was used to present exogenous KK10 
peptide antigen in activation assays. 
 
Flow cytometry reagents. Directly conjugated monoclonal antibodies (mAbs) were purchased 
from commercial sources as follows: anti-CD8-allophycocyanin-cyanine7 (APC-Cy7), anti-
CD45RA-V450, anti-CCR7-phycoerythrin (PE)-Cy7, anti-CD107a-PE-Cy5, anti-IFNγ-Alexafluor 
(AF)700, anti-TNF-PE-Cy7, anti-CTLA-4-APC, anti-BTLA-PE and anti-41BB-PE-Cy5 (BD 
Biosciences, Franklin Lakes, NJ, USA); (ii) anti-CD3-ECD and anti-2B4-PE (Beckman Coulter, 
Brea, CA, USA); (iii) anti-CD27-BV570, anti-2B4-APC and anti-CD28-AF700 (Biolegend, San 
Diego, CA, USA); (iv) anti-T-bet-AF647, anti-LIGHT-PE and anti-CD160-AF488 (eBiosciences, 
San Diego, CA, USA); (v) anti-MIP-1β-fluorescein isothiocyanate (FITC), biotinylated anti-PD-1, 
anti-Tim-3-AF700 and anti-LAG-3-FITC (R&D Systems, Abingdon, UK); anti-IL-2-APC 
(Miltenyi Biotec, Bergisch Gladbach, Germany); and, (vi) anti-CD38-ECD (Life Technologies, 
Carlsbad, CA, USA). The amine-reactive viability dye Aqua (Life Technologies) was used to 
eliminate dead cells from the analysis. Intracellular staining for T-bet was performed using the 
Transcription Factor Buffer Set (BD Pharmingen, Franklin Lakes, NJ, USA), according to the 
manufacturers instructions. Staining with all other reagents was conducted according to standard 
procedure 55. Data were acquired using a Fortessa flow cytometer (BD Biosciences) and analyzed 




with FlowJo software version 9.3.7 (TreeStar Inc, Ashland, OR, USA). Sorting of viable, CD8+ T-
cells was performed on a FACSDiva (BD) software (v8.0). A representative example of the gating 
strategy is shown in Supplemental Figure 1.  
 
Transcriptional analysis. Prior to assessing changes in gene expression, CD8+ T-cell clones and 
HLA-B27+ 722.221 target cells were treated separately with 5μg/ml purified anti-CD48 blocking 
mAb  (eBiosciences) for 1 hour at 37°C/5% CO2. Without removing the blocking antibody, anti-
CD48 treated and untreated CD8+ T-cells and 722.221 target cells were combined in an effector to 
target (E:T) ratio of 1:5, and incubated for 3 hours at 37°C/5% CO2. Upon completion of the 
activation period, viable, CD3+, CD8+ T-cells were sorted by flow cytometry (100 cells/well) into 
duplicate assay wells containing reverse transcription (RT)-PCR reaction and cDNA synthesis mix. 
Transcripts were amplified using the SuperScript III Platinum One-Step qRT-PCR system 
(Invitrogen), according to manufacturer's instructions. Quantification of gene expression was 
performed as described in 45, using the Fluidigm BioMark™ platform. Information on the primers 
and probes that were used in this study is provided in supplemental table 1. For ease of data 
interpretation, “Et” (threshold expression) values were used in the manuscript; these values 
correspond to 40-Ct, and thus increase with greater expression of a transcript; they are proportional 
to log2 RNA abundance. The two ways hierarchical clustering analysis was performed using JMP 
version 10.  
 
Intracellular cytokine staining (ICS). Prior to stimulation, a portion of CD8+ T-cells and 722.221 
cells were subjected to CD48/2B4 blockade, as described in the gene expression assessment 
methods section. The CD8+ T-cell clone and HLA-B27+ 722.221 target cells, pulsed with 1μM 
KK10 peptide or media alone, were subsequently incubated together at an E:T ratio of 1:5 for the 
first 0.5 hours with an anti-CD107a-PE-Cy5 antibody and a further 2.5 hours in the additional 




presence of monensin (2.5μg/mL; Sigma-Aldrich, St. Louis, MO, USA) and brefeldin A (5μg/mL; 
Sigma-Aldrich) at 37°C/5% CO2. The cells were collected and the staining for intracellular markers 
(TNF, IFN, MIP-1 and IL-2) was performed as described previously 5. Briefly, intracellular 
cytokine/chemokine expression and surface CD107a upregulation were determined on CD3+, CD8+ 
T-lymphocytes, following exclusion of dead cells and doublets. Data were acquired using a 
Fortessa flow cytometer (BD Biosciences) and analyzed with FlowJo software version 9.3.7 
(TreeStar Inc.).  
 
Fluorometric assessment of T-lymphocyte antigen-specific lysis (FATAL) cytotoxicity assay. 
This assay is an adaptation of a previously published protocol 56. In order to measure specific lysis 
by the CD8+ T-cell clones, target HLA-B27+ 722.221 cells were pulsed with 1μM KK10 peptide 
and labeled with 10μM Pacific blue succinimidyl ester (PBSE) dye to allow for flow cytometric 
separation from the PBSE- control cells, which were incubated with media alone and left unstained. 
Target and control 722.221 cells, and CD8+ T-cell clones were treated separately with the anti-
CD48 blocking antibody for 1 hour, or incubated with media alone. Pulsed PBSE+ and an equal 
number of unpulsed PBSE- 722.221 cells were subsequently combined with specific CD8+ T-cells, 
giving a final E:T ratio of 5:1. Control assays containing either no effectors, or a non-cognate CD8+ 
T-cell population, cultured in equivalent conditions, were set up in parallel. Following a 6 or 12 
hour assay period, the cells were harvested, stained with fluorescently-conjugated mAbs and 
acquired using a Fortessa flow cytometer (BD Biosciences). The flow cytometric assessment of 
lytic activity was based on the quantification of PBSE-labeled target cell elimination relative to 
internal PBSE- control cells. 
 
ChIP-Seq. The standard ChIP-Seq procedure has been previously described 1, 31, 37. Briefly, 105 
CD8+ T-cells were sorted by flow cytometry on the basis of CD8 expression and viability, prior to 




treatment with micrococcal nuclease (MN)ase enzyme (2 units; cat no. N3755, Sigma-Aldrich) and 
subjected to rounds of sonication by Branson 250 digital sonifier (Branson), in order to obtain 
mononucleosomes. The suspension of mononucleosomes was subsequently dialyzed to remove 
impurities and increase concentration, followed by immunoprecipitation (IP) with either an anti-
H3K4Me3 antibody (ChIP Grade ab8580; Abcam) or H3K27Me27 (ChIP Grade ab6002; Abcam). 
A non-IP control was included to assess the level of background. The IP-DNA was separated from 
the histone proteins, chemically fragmented and used to construct barcoded Illumina Truseq 
libraries. Libraries were size-selected (270 bp fragments, including adaptor), quantified, pooled, 
and sequenced on an Illumina Miseq in a 2×50-base paired-end, indexed run. The mapping 
statistics for ChIP were as follows: for ChIP-Seq with anti-H3K4Me3, total 6,612,833 reads for 
G10A, total 7,186,721 reads for G12C and total 6,526,057 reads for H8B, and uniquely mapped 
reads (5,408,938 reads for G10A (81.7%), 5,858,449 reads for G12C (81.5%) and 5,352,067 reads 
for H8B (82%)); for ChIP-Seq with anti-H3K27Me3, total 4,630,791 reads for G10A, total 
6,265,493 reads for G12C and total 6,857,447 reads for H8B, and uniquely mapped reads 
(3,362,708 reads for G10A (72.6%);  4,974,573 reads for G12C (79.3%) and  4,642,052 reads for 
H8B (67.6%)). The SICER algorithm 57 was used for peak calling with window-size of 200 bps, 
gap-size of 600bps for H3K27me3 and 400bps for H3K4me3, and a FDR (false-discovery rate) of 
< 0.01 was used identify stringent H3K4Me3-binding or H3K27-binding peaks. After peak calling, 
the statistics were as follows: for ChIP-Seq with anti-H3K4Me3, total 1,682,404 (31% of the 
uniquely mapped) enriched reads for G10A, total 2,042,792 (34.9% of the uniquely mapped) 
enriched reads for G12C and total enriched 1,700,074 (31.76% of the uniquely mapped) reads for 
H8B; for ChIP-Seq with anti-H3K27Me3, total 588,407 (17.5% of the uniquely mapped) enriched 
reads for G10A, total 826,236 (16.6% of the uniquely mapped) enriched reads for G12C and total 
855,751 (18.4% of the uniquely mapped)  enriched reads for H8B. The sequence reads and 




expression data have been deposited in the NCBI Short Reads Archive (Reference number: 
SRP051786). 
Tetramer dilution assay. TCR avidity was measured using tetramer dilution assays. Briefly, CD8+ 
T-cell clones were incubated with cognate tetramer at a range of concentrations (10 μg/mL to 
0.0015 μg/mL in 1/3 dilutions) for 30 minutes at 4°C, then stained for CD8 expression before 
fixation. The percentage and fluorescence intensity of tetramer+ CD8+ T-cells at each tetramer 
concentration was determined by flow cytometry. 
 
Statistical analysis. Comparisons between groups were performed using the non-parametric 
Wilcoxon signed rank test in Prism 5 (GraphPad). P values <0.05 were considered significant. 
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Figure Legends  
Figure 1. Immunomodulatory molecule expression on CD8+ T-cells. The pattern of co-inhibitory 
and co-stimulatory receptor expression on resting and activated PBMCs, averaged over three 
different donors (a and b) and CD8+ T-cell clones G12C (black), G10A (grey) and H8B (white) (c 
and d). Non-specific stimulation of PBMC samples was achieved using anti-CD3 and anti-CD28 
antibody-coated microbeads for 3 hours. Immunomodulatory molecule expression was measured by 
flow cytometry, gating on the viable, single-cell CD3+, CD8+ T-cell population. In parallel, CD8+ 
T-cell clones were stimulated for 3 hours with HLA-B27+ 722.221 target cells, presenting 
exogenously pulsed-on 1M KK10 peptide. Phenotypic profiling of the CD8+ T-cells was achieved 
by evaluating the expression of the markers CD27, CD28, CD45RA and CCR7. (e) Representative 
flow cytometry plots showing the phenotype of one of the CD8+ T-cell clones (G12C, black dots) 
overlaid onto the phenotype of a reference CD8+ T-cell population within a healthy donor PBMC 
sample (grey density plot). (f) A staggered flow cytometry histogram plot showing the MFIs 
(indicated by numbers on the right) of surface 2B4 staining for clones G12C, G10A and H8B 
compared to reference PBMC-derived CD8+ T-cell population at various stages of differentiation. 
CM; central memory subset, E-EM, I-EM and L-EM; early, intermediate and late effector memory 
subsets, respectively. Representative line graphs from a single experiment out of five independent 
experiments shown (a and b). Error bars indicate SD from the mean of three independent 
experiments (c and d).  
 
Figure 2. The effect of blocking the 2B4/CD48 interaction on the transcriptional profile of CD8+ T-
cell clones G12C, G10A and H8B. (a) Heat map representation of the transcriptional signature for 
the G12C, G10A and H8B clones. The black frame highlights the impact of blocking the 
2B4/CD48 interaction on the expression of genes relating to CD8+ T-cell function, whose levels are 
altered upon antigenic stimulation (3 hour stimulation with HLA-B27+ 722.221 target cells 




presenting 1M KK10 peptide). (b) Et graphs for selected genes, providing a quantitative measure 
for the impact of 2B4/CD48 blockade on the expression of genes associated with CD8+ T-cell 
effector function. Assays were set up in parallel using CD8+ T-cell clones and 722.221 target cells 
that had been pre-treated (for 1 hour) with an anti-CD48 blocking antibody, or left untreated. 
Transcriptional analysis was performed on duplicate FACS sorts of 100 cells/well. Error bars 
indicate SD from the mean of two replicates.  
 
Figure 3. The influence of blocking the 2B4/CD48 interaction on CD8+ T-cell effector functions 
and cytotoxicity. (a) Degranulation (upregulation of CD107a) by the CD8+ T-cell clones G12C, 
G10A and H8B following a 3 hour stimulation with HLA-B27+ 722.221 cells presenting 1M 
KK10 peptide, either following treatment with an anti-CD48 blocking antibody (administered 
individually to CD8+ T-cells and HLA-B27+ 722.221 target cells for 1 hour, prior to initiation of the 
activation assay) or media alone. (b) Representative FATAL cytotoxicity assay histograms (from a 
single experiment reproduced two times) showing the lysis of the 1M KK10-pulsed HLA-B27+ 
722.221 target cells (PBSE+ peak) relative to an internal unpulsed 722.221 control population 
(PBSE- peak), during a 6 hour incubation period, following pre-treatment with an anti-CD48 
antibody or in the absence of CD48 blocking. Specific lysis by clones G12C, G10A and H8B was 
assessed against a reference assay containing no CD8+ T-cells. (c) Specific lysis (%) of the 722.221 
target population by clones G12C, G10A and H8B, averaged over two separate 6 hour and two 12 
hour experiments. (d) Effector cytokine and chemokine production by clones G12C, G10A and 
H8B (averaged over four independent assays), measured by ICS following a 3 hour period of 
stimulation with HLA-B27+ 722.221 cells presenting 1M KK10 peptide, with or without CD48 
blocking. Error bars (for a, c and d) indicate SD from the mean of three independent experiments. 
Statistical comparisons between groups +/- anti-CD48 blocking (a, c and d) were performed using 




the Wilcoxon signed rank test. P values <0.05 were considered significant. No statistical 
significance was achieved for data presented in a and d.  
 
 
Figure 4. Epigenetic and transcriptional profiling for selected genes, performed on resting CD8+ T-
cell clones G12C, G10A and H8B. H3K4Me3 ChIP-Seq data, showing an open chromatin state at 
the promoters of genes encoding molecules associated with (a) CD8+ T-cell effector function  
(PRF1; perforin, GZMB; granzyme B, LAMP1; LAMP1/CD107a and TBX21; T-bet) and (b) the 
2B4/CD48 signaling pathway (CD244; 2B4, CD48, SH2D1A; SAP, and Fyn) (c) Basal expression 
of selected genes associated with CD8+ T-cell function. Error bars indicate SD from the mean of 
two replicates.  
 
Figure 5. The effect of 2B4/CD48 blockade on T-bet expression by resting and activated CD8+ T-
cells. (a) Representative flow cytometry histograms (showing data from one of two independent 
experiments), showing intracellular T-bet expression within phenotypically defined populations of 
CD8+ T-cells (in a PBMC sample) and CD8+ T-cell clones. EM; effector memory, L-EM; late 
effector memory, FMO; fluorescence minus one. (b) A flow cytometry plot (representative of two 
independent experiments) showing the increase in T-bet expression by a CD8+ T-cell clone (G12C 
used as an example) on activation with 722.221 target cells presenting cognate KK10 antigen. (c) 
Assessment of T-bet expression by resting or antigen-stimulated CD8+ T-cell clones G12C, G10A 
and H8B in the presence or absence of an anti-CD48 blocking antibody. (d) KK10/HLA-B27 
tetramer titration curves for clones G12C, G10A and H8B, used as a measure of TCR avidity. Error 
bars indicate SD from the mean of two independent experiments.  
 
 
 
